CAGR of 5.82% expected from 2022 to 2026, reaching US$15.86 billion in 2026

DUBLIN, February 21, 2022 /PRNewswire/ — The “Global Hemophilia Market (by Treatment Regimen, Type, and Therapy): Insights and Forecast with Potential Impact of COVID-19 (2022-2026)” report has been added to from offer.

Research and Markets Logo

The Global Hemophilia Market is Expected to Reach US$15.86 billion in 2026, growing at a CAGR of 5.82% over the period 2022-2026.

Market growth has been driven by factors such as increasing healthcare expenditure, increasing volume of identified hemophilia patients, increased focus on prophylactic treatment, increasing male population, and government initiatives favorable. The market is expected to face some challenges such as the high cost of treatments and the reluctance to switch to new therapies. To overcome these challenges, the market would witness some key trends such as the development of new treatments for hemophilia and the growing popularity of gene therapy.

The global hemophilia market by treatment regimen can be segmented into prophylaxis and on-demand. In 2021, the highest share was held by the prophylaxis segment, followed by the on-demand segment. The global hemophilia market by type can be segmented as follows: hemophilia A and hemophilia B, where hemophilia A held a larger market share in 2021. The global hemophilia market by therapy can be segmented as follows : replacement therapy and ITI therapy. The dominant market share in 2021 was held by the replacement therapy segment.

The global hemophilia market by region can be segmented into the following regions: North America, Europe and Asia Pacific. In 2021, the dominant market share was held by North Americafollowed by Europe and Asia Pacific. Factors such as increasing prevalence of hemophilia, increasing knowledge of individuals regarding different treatment methods, and increasing inclination towards prophylactic treatment have contributed to the growth of the North American market.

Market dynamics

Growth engines

  • Increased emphasis on prophylactic treatment

  • Increase in diagnosis rate

  • Rise in global health spending

  • Male population increase

  • Supportive government initiatives

Key trends and developments

  • Focus on extended half-life therapies

  • Development of new treatments for hemophilia

  • Popularity of gene therapy


Report Scope:

  • The report provides a comprehensive analysis of the global hemophilia market, segmented into hemophilia A and hemophilia B

  • Major regional markets North America, Europe and Asia Pacific with the United States country analysis were analyzed

  • Market dynamics such as growth drivers, market trends, and challenges are thoroughly analyzed

  • The competitive landscape of the market, along with company profiles of key players (Pfizer Inc., Bayer Group, Sanofi SA, Takeda Pharmaceutical Company, Novo Nordisk and CSL Limited) are also presented in detail

Main topics covered:

1. Market Overview
1.1 Hemophilia
1.2 Types of hemophilia
1.3 Signs and symptoms
1.4 Diagnosis of hemophilia
1.5 Hemophilia treatment

2. Impact of COVID-19
2.1 Impact on the global economy
2.2 Global prevalence of COVID-19
2.3 Impact on health expenditure
2.4 Post-COVID scenario

3. Global Market Analysis
3.1 Global Hemophilia Market by Value
3.2 Global Hemophilia Market Forecast by Value
3.3 Global Hemophilia Market by Treatment Regimen
3.4 Global Hemophilia Market by Type
3.5 Global Hemophilia Therapy Market
3.6 Global Hemophilia Market by Region

4. Regional market To analyse

5. Market dynamics

6. Competitive landscape
6.1 Global market
6.1.1 Revenue Comparison – Key Players
6.1.2 Market Cap Comparison – Key Players
6.1.3 Research and Development Expenditure Comparison – Key Players
6.1.4 Global Hemophilia A Market Share by Company
6.1.5 Global Hemophilia A Factor VIII Products Market Share by Company
6.1.6 Global Hemophilia A FVIII Gene Therapy Market Share Forecast
6.1.7 Global Hemophilia B Market Share by Company
6.1.8 Global Hemophilia B Factor IX Products Market Share Forecast
6.1.9 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast
6.1.10 Key Players – Top Anti-Hemophilia Products
6.2 The American market
6.3 European market

7. Company Profiles

  • CSL Limited

  • Novo Nordisk

  • Sanofi SA

  • Pfizer Inc.

For more information on this report, visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Woodsenior

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716



Show original content:–to-reach-us15-86 -billions-in-2026–301486448.html

SOURCE Research and Markets